Clinical Trials Web Sites Don't Disclose Study Risks
NEW YORK (Reuters Health) May 29
Web sites that provide listings of
clinical trials are growing in popularity, but a new US government
inspection reveals a potential danger for patients.
None of the sites visited by federal inspectors disclose the risks of
participating in a study, while less than a third give the names of the
Such omissions may leave patients with false impressions, undermining the
informed consent process, the Department of Health and Human Services
Office of Inspector General (OIG) cautioned in a report issued Tuesday
The OIG urges the US Food and Drug Administration (FDA) and the federal
Office for Human Research Protections (OHRP) to work together to produce a
common set of expectations to help ensure the credibility of clinical
trials Web sites.
Federal inspectors reviewed 22 clinical trials Web sites and 110 listings
on those sites. The examination includes three federal Web sites as well as
a number of third-party Web sites and sites run by institutional and
pharmaceutical sponsors. They also interviewed Web site sponsors, federal
officials and members of institutional review boards (IRBs), whose
responsibility is to protect the welfare of trial participants.
While 29 Web sites present the benefits of participating in a trial, none
describe the risks, it found. Moreover, most of the benefits focus on
convenience and incentives, such as free parking and payment for
participation in a trial, not the clinical aspects of the trial.
"These benefits can be misleading if not tempered by a statement that risks
are involved," the report notes.
A majority (63%) of sites did not indicate the phase of the clinical trial,
making it impossible for a patient to distinguish a phase I trial that is
designed strictly to test the safety of an experimental drug from a phase
III trial focusing on efficacy and safety, it said.
A general description
of the protocol was missing from 51% of the sites reviewed.
The report offers several examples of information that overstated the
benefits of a clinical trial.
Another area of concern involved lapses in Web site privacy policies. Of
the 13 sites that collect personal information from visitors, most do not
disclose how they will use the information, the OIG reported.
And while 12 sites generate revenue, half of them fail to disclose how they
do so. Financial relationships can affect how a site's information is
interpreted, the report said.
The FDA and OHRP should foster the development of voluntary standards for
clinical trials Web sites and encourage Web sites to voluntarily submit to
periodic review by an IRB or accrediting organization, the OIG said.
Those agencies also should stipulate that risk and benefit information in
clinical trial listings and any prescreening information collected from
individuals for specific trials is subject to IRB review and approval, it
Breast Cancer News is brought to you by the The MID HUDSON OPTIONS PROJECT,
INC a grassroots Breast Cancer Health Advocacy, Support and Activist Group.
|Remember we are NOT Doctors and have NO medical training.|
This site is like an Encyclopedia - there are many pages, many links on many topics.
Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.